Benzinga | Jul 13, 2021 10:18AM EDT

Palisade Bio, University of California Team Up For Target Identification, Discovery, Development

* Palisade Bio Inc (NASDAQ:PALI) has entered into an exclusive license with the Regents of the University of California, expanding its technology for detecting enzymatic protease activity in human clinical samples.

* Under the terms of this agreement, the Company receives a worldwide exclusive license to patent rights covering certain engineered substrates and their use in measuring degradative enzymes for disease conditions.

* Price Action: PALI shares are up 3.28% at $3.78 during the market session on the last check Tuesday.